Brief: Astellas And Pfizer's Xtandi™ (Enzalutamide) Shows Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate Cancer
22/05/2025 22:58
Astellas Pharma Inc 4503.T: ASTELLAS AND PFIZER'S XTANDI™ (ENZALUTAMIDE) SHOWS LONG-TERM OVERALL SURVIVAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PFIZER INC - XTANDI PLUS ADT REDUCES RISK OF DEATH BY 30% PFIZER INC - XTANDI PLUS ADT SHOWS 66% FIVE-YEAR SURVIVAL PROBABILITY PFIZER INC - NO NEW SAFETY SIGNALS IDENTIFIED IN FIVE-YEAR FOLLOW-UP Source text: ID:nPn7lLMQra Further company coverage: 4503.T
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn